EUCTR2008-007753-12-AT进行中（未招募）不适用
The pharmacokinetics of anidulafungin during continuous venovenous hemofiltration
MUW, Universitätsklinik für Innere Medizin I, Abteilung für Infektionskrankheiten und Tropenmedizin0 个研究点开始时间: 2009年1月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a)Age 19 to 70 years
- •b)Suspected or proven infection requiring parenteral antifungal therapy.
- •c)Continuous venovenous hemofiltration because of an acute renal failure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a)Known history of hypersensitivity to echinocandins.
- •b)An expected survival of less than three days.
- •c)Known alcohol dependency, epilepsy, pregnancy or liver failure.
- •d)Neutropenic patients
研究者
相似试验
已完成
4 期
Pharmacokinetics of anidulafungin in critically ill patients with invasive candidiasisinvasive candidiasisinvasive fungal infection10017528NL-OMON32922niversitair Medisch Centrum Groningen20
已完成
4 期
Anidulafungin pharmacokinetics given as a single intravenous dose to obese patients (ADOPT).Candidiasis / Fungal infections10017528NL-OMON40398niversitair Medisch Centrum Sint Radboud8
进行中（未招募）
不适用
Farmacocinética de anidulafungina en pacientes sometidos a hemodiafiltración.Tratamiento de candidiasis Invasiva en paciente adulto no neutropenico.MedDRA version: 13Level: LLTClassification code 10042938EUCTR2010-024457-36-ESDr.Gerardo Aguilar Dr.Francisco Martí Hospital Clínico de Valencia Ser. Anestesiología y Reanimación
进行中（未招募）
不适用
Pharmacokinetics of anidulafungin (Ecalta ®) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative chemotherapy or patients receiving intensive chemotherapy for AML-MDS who are at high risk for developing invasive fungal diseasePharmacokinetics of anidulafungin (Ecalta ®) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative chemotherapy or patients receiving intensive chemotherapy for AML-MDS who are at high risk for developing invasive fungal diseaseMedDRA version: 9.1Level: LLTClassification code 10017533Term: Fungal infectionMedDRA version: 12.1Level: HLGTClassification code 10024324Term: LeukaemiasEUCTR2010-018752-27-NLRadboud University Nijmegen Medical Centre
已完成
2 期
Pharmacokinetics of anidulafungin (Ecalta ®) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative chemotherapy or patients receiving intensive chemotherapy for AML-MDS who are at high risk for developing invasive fungal diseasefungal infectionhematology patients10017528NL-OMON34306niversitair Medisch Centrum Sint Radboud20